Tenpoint Therapeutics welcomes Dr. Stephen Lane as Chief Medical Officer
Dr. Lane brings extensive ophthalmology experience. He oversees clinical development, medical affairs, and pharmacovigilance.
See the latest news and media coverage for Tenpoint Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Eye therapeutics developer for aging vision disorders
tenpointtherapeutics.comLast updated
In short: Tenpoint Therapeutics merged with Visus Therapeutics, secured significant financing, and launched its FDA-approved presbyopia treatment YUVEZZI.
Dr. Lane brings extensive ophthalmology experience. He oversees clinical development, medical affairs, and pharmacovigilance.
YUVEZZI™ is carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%.
YUVEZZI™ is carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%.
YUVEZZI is the first dual-agent eye drop for presbyopia treatment, based on Phase 3 trials, available Q2 2026.
The Ritedose Corporation, Inc. (Ritedose), the largest contract development manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit dose...
Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced the appointment...
Tenpoint Therapeutics, a leading ophthalmic manufacturer, and PHIL Inc., an all-in-one digital hub and Direct-to-Patient platform, today announced the launch of a Direct-to-Patient (DTP) cash...
Tenpoint Therapeutics, Ltd., a global, commercial-stage ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced that YUVEZZI...
Track Tenpoint Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.